Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials | BMC Psychiatry BioMed Central Open Access Research article Maintenance of response with atypical antipsychotics in the treatment of schizophrenia a post-hoc analysis of 5 double-blind randomized clinical trials Virginia Stauffer 1 Haya Ascher-Svanum 1 Lin Liuf1 Tamara Ballt2 and Robert Conleyf1 Address Lilly Research Laboratories Indianapolis IN USA and 2i3 Statprobe Ann Arbor MI USA Email Virginia Stauffer - stauffer_virginia@lilly.com Haya Ascher-Svanum - ascher-svanum_haya@lilly.com Lin Liu - liu_lin_ll@lilly.com Tamara Ball - tamara.ball@i3statprobe.com Robert Conley - rconley@lilly.com Corresponding author fEqual contributors Published 31 March 2009 Received I October 2008 BMC Psychiatry 2009 9 13 doi 10.1186 1471-244X-9-13 Accepted 31 March 2009 This article is available from http www.biomedcentral.com I47I-244X 9 I3 2009 Stauffer et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background How long an antipsychotic is effective in maintaining response is important in choosing the correct treatment for people with schizophrenia. This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine risperidone quetiapine ziprasidone or aripiprazole. Methods This was a post-hoc analysis using data from 5 double-blind randomized comparative trials of 24 or 28 weeks duration in which olanzapine was compared to risperidone 1 study N 339 quetiapine 1 study N 346 ziprasidone 2 studies N 548 and 394 or aripiprazole 1 study N 566 for treatment of schizophrenia. For each study time to loss of response in patients who met criteria for response at Week 8 and the proportion of patients who lost response following Week 8 were compared by treatment group. The .
